Show simple item record

dc.contributor.authorClamp, Andrew R
dc.contributor.authorMcNeish, I
dc.contributor.authorDean, A
dc.contributor.authorGallardo-Rincon, D
dc.contributor.authorKim, J
dc.contributor.authorO'Donnell, D
dc.contributor.authorHook, J
dc.contributor.authorBlagden, S
dc.contributor.authorBrenton, J
dc.contributor.authorNaik, R
dc.contributor.authorPerren, T
dc.contributor.authorSundar, S
dc.contributor.authorCook, A
dc.contributor.authorJames, E
dc.contributor.authorGabra, H
dc.contributor.authorLord, R
dc.contributor.authorHall, M
dc.contributor.authorDark, G
dc.contributor.authorKaplan, R
dc.contributor.authorLedermann, J
dc.date.accessioned2019-04-29T09:49:01Z
dc.date.available2019-04-29T09:49:01Z
dc.date.issued2018en
dc.identifier.citationClamp AR, McNeish IA, Dean A, Gallardo-Rincon D, Kim JW, O�Donnell DM, et al. 943PD Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Ann Oncol. 2018;29(suppl_8):336.en
dc.identifier.doi10.1093/annonc/mdy285.151en
dc.identifier.urihttp://hdl.handle.net/10541/621807
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy285.151en
dc.titleResponse to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatmenten
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-04-20T10:56:11Z


Files in this item

Thumbnail
Name:
561659.pdf
Size:
93.91Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record